SCHEDULE: Armistice Capital Discloses 7.75% Stake in Arcadia Biosciences

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 7.75% in Arcadia Biosciences, Inc., holding 159,390 shares as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd collectively hold 159,390 shares of Arcadia Biosciences, Inc. common stock.
• This represents a 7.75% ownership stake in the company.
• The filing is made under Schedule 13G, indicating passive investment.
• Armistice Capital, LLC is the investment manager for the Master Fund, which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.
• The Master Fund disclaims beneficial ownership due to the investment management agreement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a standard disclosure of beneficial ownership, indicating a significant passive stake but providing no new operational or financial information about the company itself.

Positives

• Significant passive stake (7.75%) held by Armistice Capital, LLC and Steven Boyd, suggesting confidence in Arcadia Biosciences' long-term prospects.
• The filing indicates a passive investment strategy, which typically implies a focus on the company's fundamental value rather than short-term activism.

Negatives

• The filing does not contain any negative financial or operational information about Arcadia Biosciences; it solely reports ownership.

Risks

• The Master Fund's disclaimer of beneficial ownership due to the investment management agreement could introduce complexity in understanding ultimate control.
• While this filing is passive, future actions by Armistice Capital or Steven Boyd could potentially influence the company's control or strategic direction.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Arcadia Biosciences.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant passive ownership stakes, as reported by Armistice Capital in Arcadia Biosciences, are common in the biotechnology and agricultural technology sectors. Such filings often precede or coincide with shifts in investor sentiment or strategic evaluations of the company's market position and growth potential.

Stakeholder Impact

• Shareholders: The increased visibility of a significant passive investor may influence market perception and potentially lead to increased trading volume.
• Management: May face increased scrutiny or engagement from Armistice Capital regarding company strategy and performance.
• Creditors: No immediate impact expected, as the filing pertains to equity ownership.

Next Steps

• Monitor future filings from Armistice Capital, LLC and Steven Boyd for any changes in their ownership stake or investment strategy.
• Observe Arcadia Biosciences' operational and financial performance for potential impact from significant passive investors.

Key Dates

Keywords

Arcadia Biosciences, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Passive Investment